Casadei‐Gardini A, Scartozzi M, Tada T, et al. - In balanced cohorts of patients with unresectable hepatocellular carcinoma who were receiving either sorafenib or lenvatinib, researchers investigated the apparent equivalence of these agents utilizing data from common clinical practice. Using inverse probability of treatment weighting (IPTW) methodology, clinical features of lenvatinib and sorafenib patients were balanced. The primary endpoint was overall survival. This study involved 385 patients treated with lenvatinib, and 555 managed with sorafenib. No survival advantage over sorafenib was seen with lenvatinib in the unadjusted cohort. Following IPTW adjustment, there was no survival benefit of lenvatinib over sorafenib, even when baseline features were balanced. Overall, findings not only corroborated the outcomes from randomized controlled trials in the real‐life setting, but also indicate that some benefit can be expected in earlier stages.